PDE7A

(redirected from PDE7)

PDE7A

A gene on chromosome 8q13 that encodes a cyclic nucleotide phosphodiesterase, which hydrolyses the second messenger cAMP to AMP and is thus involved in regulating physiological processes. PDE7A is thought to have a role in signal transduction in muscle.
References in periodicals archive ?
These increased expenses were partially offset by lower preclinical activity on the PDE7 program.
Omeros intends to use the net proceeds of the offering for general corporate purposes, including expenses related to the potential commercialization of OMS302 for intraocular lens replacement, as well as for research and development expenses, such as funding planned clinical trials for its OMS103HP, PDE10, MASP-2 and PDE7 programs.
Our MASP-2 and PDE7 programs are also slated for the clinic this year.
In addition to our progress in the OMS824 program, we plan to submit the NDA next quarter and the MAA mid-year for OMS302, our ophthalmic drug product, and we remain on track to advance our MASP-2 and PDE7 programs into the clinic in the coming months.
Omeros believes that it is the first to discover the link between PDE7 and any addiction or compulsive disorder, and the Company is establishing a broad intellectual property position around this discovery.
These increases were partially offset by lower expenses related to Omeros' OMS302 and OMS103HP Phase 3 clinical programs and its PDE10, PDE7 and Plasmin programs.
The increase during the quarter was also the result of higher expenses incurred in Omeros' GPCR program as well as one-time manufacturing and toxicology study costs intended to support clinical trials for Omeros' PDE10 and PDE7 programs.
We also made significant progress in the rest of our pipeline - PDE10, PDE7, MASP-2 and our anti-plasmin programs are all advancing to the clinic, and our GPCR platform continued its success, finding functional compounds for four additional orphan receptors.
The Company previously demonstrated that PDE7 inhibitors showed strong effects in models of cocaine addiction and binge eating.
Currently, Omeros is advancing PDE7 inhibitors for the treatment of these as well as movement disorders.
for use in Omeros' PDE7 program, which is focused on the treatment of movement disorders.
for use in its PDE7 program, which is focused on the treatment of movement disorders.